Prifemilast (HPP737) vs Roflumilast (Zoryve foam)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

Prifemilast (HPP737)

Developed by Newsoara Biopharma under a licence from vTv Therapeutics

Phase 3 in Psoriasissmall molecule
Partial signal

NCT07712731 · Phase 3 · completed

The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures.

Reported efficacy

To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75); (From enrollment to end of treatment at 16 weeks); To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)" (From enrollment to end of treatment at 16 weeks): Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). (met)

Result source: NCT07712731

Roflumilast (Zoryve foam)

Marketed by Arcutis Biotherapeutics and partners

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPrifemilast (HPP737)Roflumilast (Zoryve foam)
PASI 75—Not posted · NCT0771273150.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582
PASI 90—Not posted · NCT07712731—Not reported
PASI 100—Not posted · NCT07712731—Not reported
sPGA 0/1—Not posted · NCT07712731—Not reported
DLQI, change—Not posted · NCT07712731—Not reported

PASI 75

Prifemilast (HPP737)
—Not posted · NCT07712731
Roflumilast (Zoryve foam)
50.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582

PASI 90

Prifemilast (HPP737)
—Not posted · NCT07712731
Roflumilast (Zoryve foam)
—Not reported

PASI 100

Prifemilast (HPP737)
—Not posted · NCT07712731
Roflumilast (Zoryve foam)
—Not reported

sPGA 0/1

Prifemilast (HPP737)
—Not posted · NCT07712731
Roflumilast (Zoryve foam)
—Not reported

DLQI, change

Prifemilast (HPP737)
—Not posted · NCT07712731
Roflumilast (Zoryve foam)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Prifemilast (HPP737)
Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). NCT07712731 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
The placebo-controlled Phase 3 was positive per the sponsor, with responses kept through 52 weeks; figures were not given (2026-10-09). NCT07712705 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Prifemilast (HPP737): 0 of 4 rows · Roflumilast (Zoryve foam): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRoflumilast (Zoryve foam)
Dropout rate
11%0.3% foama
NCT05028582 · Phase 3
show 1 more result
11.5%
NCT04128007 · Phase 2
Discontinued due to AEs
1.8%0.3% foama
NCT05028582 · Phase 3
show 1 more result
2.5%
NCT04128007 · Phase 2
Serious AEs
0.7%0.3% foama
NCT05028582 · Phase 3
show 1 more result
0.5%
NCT04128007 · Phase 2
Most frequent reported AEs—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roflumilast (Zoryve foam)

Scalp IGA 66.4% (n=281) vs 27.8% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 3 more results
30.4% (n=281) vs 11.7% (n=151) placebo @ 2wk0.3% foam
NCT05028582 · Phase 3
53.8% (n=281) vs 19.5% (n=151) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
59.1% (n=181) vs 11.4% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 107 Participants as posted
Body IGA 45.5% (n=281) vs 20.1% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
40.3% (n=181) vs 6.8% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 73 Participants as posted
Scalp Itch NRS 25.2% (n=203) vs 8% (n=123) placebo @ 2wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 5 more results
46.2% (n=203) vs 16.8% (n=123) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
65.3% (n=203) vs 30.3% (n=123) placebo @ 8wk0.3% foam
NCT05028582 · Phase 3
44.6% (n=166) vs 15.6% (n=90) placebo @ 2wk*
NCT04128007 · Phase 2 · converted to % from 74 Participants as posted
59% (n=166) vs 21.1% (n=90) placebo @ 4wk*
NCT04128007 · Phase 2 · converted to % from 98 Participants as posted
66.3% (n=166) vs 16.7% (n=90) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 110 Participants as posted
Itch NRS -0.44 vs -0.09 placebo score @ 0.14wk0.3% foam
absolute change · score
NCT05028582 · Phase 3
show 2 more results
-1.11 vs -0.36 placebo score @ 0.43wk0.3% foam
NCT05028582 · Phase 3
-1.08 vs -0.53 placebo score @ 1wk0.3% foam
NCT05028582 · Phase 3
Itch NRS 63.1% (n=203) vs 30.1% (n=110) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PASI 75 50.1% (n=281) vs 16.8% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Itch Pain Scaling -10.87 vs -5.75 placebo score @ 8wk0.3% foam
absolute change · score
NCT05028582 · Phase 3
PSD Itching Score Zero 31.7% (n=274) vs 10% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Pain Score Zero 64.9% (n=274) vs 40.3% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Scaling Score Zero 41.5% (n=274) vs 13.6% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Total Score Zero 19.6% (n=274) vs 7.1% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSSI 75 70.9% (n=281) vs 31.3% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
67.2% (n=180) vs 21.8% (n=87) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 121 Participants as posted

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Prifemilast (HPP737)'s landscape · Roflumilast (Zoryve foam)'s landscape